Compare ADMA Biologics Inc (ADMA) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs McCormick & Company, Incorporated — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while McCormick & Company, Incorporated trades at $51.84 (market cap $14.04B). The key difference: McCormick & Company, Incorporated is far larger — about 6.6× ADMA Biologics Inc's market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MKC | |
|---|---|---|
Market Cap | $2.13B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $72.90 |
52-Week Low | $7.60 | $45.60 |
Enterprise Value | $2.20B | $18.64B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
McCormick (MKC) trades at $52.22, down 2.3% today but maintains a bullish technical outlook with strong support at $51. The company delivered solid Q2 2026 results with earnings of $0.80 per share beating estimates, driven by 14% constant currency sales growth and margin expansion to 40.2%. Valuation metrics appear attractive with a P/E of 8.62 and P/S of 1.89, while analyst consensus targets $59.67 representing 14% upside potential.
The investment case centers on MKC's defensive positioning in consumer staples, transformative Unilever food business combination potential, and improving profitability. Key risks include soft consumer volume trends in the Americas and execution challenges from the pending acquisition. With 36.7% of analysts rating the stock a buy and institutional ownership stable, MKC offers value with a 4% dividend yield amid ongoing operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
